Economic Evaluation of Manitoba Health Lines in the Management of Congestive Heart Failure

Yang, Cui; Doupe, Malcolm; Katz, Alan; Nyhof, Paul; Forget, Evelyn L.

doi:10.12927/hcpol.2013.23620

Cited by 15 publications

(34 citation statements)

References 88 publications

(511 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…eHealth technologies evaluated were telehealth [ 9 – 12 ], a computerized decision support system [ 13 ], telemonitoring [ 14 , 15 ], web-based physical activity intervention [ 16 ], telecare [ 17 ], and internet delivered cognitive behavior therapy (iCBT) [ 18 , 19 ] compared with usual (or standard) care in patients with diabetes [ 9 , 13 , 16 , 17 ], congestive heart failure [ 14 , 15 , 17 ], cardiovascular disease [ 11 , 12 ], colon cancer [ 16 ], breast cancer [ 16 ], acute myocardial infarctions [ 16 ], stroke [ 16 ], chronic obstructive pulmonary disease [ 10 ], generalized anxiety disorder [ 18 ], and depression [ 19 ]. These studies were conducted from the perspective of public health care system (i.e.…”

Section: Resultsmentioning

confidence: 99%

“…These studies were conducted from the perspective of public health care system (i.e. The Netherlands [ 13 , 16 ], Canada [ 15 ], United Kingdom [ 11 , 12 , 17 ], Spain [ 10 ], and Australia [ 18 , 19 ]). Two studies used simulation modeling [ 11 , 16 ], nine studies used statistical (regression) modeling [ 9 , 10 , 12 , 14 , 15 , 17 – 19 ], and one used both simulation and regression modeling [ 13 ] to predict costs and QALYs.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Economic evaluations of eHealth technologies: A systematic review

et al. 2018

View full text Add to dashboard Cite

BackgroundInnovations in eHealth technologies have the potential to help older adults live independently, maintain their quality of life, and to reduce their health system dependency and health care expenditure. The objective of this study was to systematically review and appraise the quality of cost-effectiveness or utility studies assessing eHealth technologies in study populations involving older adults.MethodsWe systematically searched multiple databases (MEDLINE, EMBASE, CINAHL, NHS EED, and PsycINFO) for peer-reviewed studies published in English from 2000 to 2016 that examined cost-effectiveness (or utility) of eHealth technologies. The reporting quality of included studies was appraised using the Consolidated Health Economic Evaluation Reporting Standards statement.ResultsEleven full text articles met the inclusion criteria representing public and private health care systems. eHealth technologies evaluated by these studies includes computerized decision support system, a web-based physical activity intervention, internet-delivered cognitive behavioral therapy, telecare, and telehealth. Overall, the reporting quality of the studies included in the review was varied. Most studies demonstrated efficacy and cost-effectiveness of an intervention using a randomized control trial and statistical modeling, respectively. This review found limited information on the feasibility of adopting these technologies based on economic and organizational factors.ConclusionsThis review identified few economic evaluations of eHealth technologies that included older adults. The quality of the current evidence is limited and further research is warranted to clearly demonstrate the long-term cost-effectiveness of eHealth technologies from the health care system and societal perspectives.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Economic evaluations of eHealth technologies: A systematic review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In addition, we will explore the possibility of building a decision analytic model that will examine the potential long-term economic impact of the intervention after the study period 72. This economic model will use various data sources to estimate costs including the study,73 74 published literature67–69 and expert opinion.…”

Section: Proposed Analysesmentioning

confidence: 99%

Physical activity trails in an urban setting and cardiovascular disease morbidity and mortality in Winnipeg, Manitoba, Canada: a study protocol for a natural experiment

Hobin

Swanson²,

Booth

et al. 2020

BMJ Open

View full text Add to dashboard Cite

IntroductionAspects of the built environment that support physical activity are associated with better population health outcomes. Few experimental data exist to support these observations. This protocol describes the study of the creation of urban trials on cardiovascular disease (CVD)-related morbidity and mortality in a large urban centre.Methods and analysisBetween 2008 and 2010, the city of Winnipeg, Canada, built four, paved, multiuse (eg, cycling, walking and running), two-lane trails that are 5–8 km long and span ~60 neighbourhoods. Linking a population-based health data with census and environmental data, we will perform an interrupted time series analysis to assess the impact of this natural experiment on CVD-related morbidity and mortality among individuals 30–65 years of age residing within 400–1200 m of the trail. The primary outcome of interest is a composite measure of incident major adverse CVD events (ie, CVD-related mortality, ischaemic heart disease, stroke and congestive heart failure). The secondary outcome of interest is a composite measure of incident CVD-related risk factors (ie, diabetes, hypertension and dyslipidaemia). Outcomes will be assessed quarterly in the 10 years before the intervention and 5 years following the intervention, with a 4-year interruption. We will adjust analyses for differences in age, sex, ethnicity, immigration status, income, gentrification and other aspects of the built environment (ie, greenspace, fitness/recreation centres and walkability). We will also assess trail use and trail user profiles using field data collection methods.Ethics and disseminationEthical approvals for the study have been granted by the Health Research Ethics Board at the University of Manitoba and the Health Information Privacy Committee within the Winnipeg Regional Health Authority. We have adopted an integrated knowledge translation approach. Information will be disseminated with public and government partners.Trial registration numberNCT04057417.

show abstract

“…www.nature.com/aps Lu HI et al Acta Pharmacologica Sinica npg expenses worldwide [6,7] . In addition, although the etiology and mechanisms of HF have been extensively investigated and various therapeutic strategies have been developed [8][9][10] , the morbidity and mortality of patients with advanced HF are still extremely high [1][2][3][6][7][8] .…”

Section: Introductionmentioning

confidence: 99%

“…In addition, although the etiology and mechanisms of HF have been extensively investigated and various therapeutic strategies have been developed [8][9][10] , the morbidity and mortality of patients with advanced HF are still extremely high [1][2][3][6][7][8] . Accordingly, the development of novel therapeutic options is of the utmost importance for scientists conducting basic research and especially for physicians who are the first-line managers of these patients.…”

Section: Introductionmentioning

confidence: 99%

Administration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice

Lu¹,

Huang²,

Sung³

et al. 2016

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim: Antioxidant peptide SS-31 is a class of cell-permeable small peptides, which selectively resides on the inner mito¬chondrial membrane and possesses intrinsic mitochondrial protective capacities. In this study we investigated the therapeutic effects of antioxidant peptide SS-31 on transverse aortic constriction (TAC)-induced pulmonary arterial hypertension (PAH) in a murine model. Methods: Adult male mice were divided into 3 groups: sham-operated mice, TAC mice, and TAC+SS-31 mice that underwent TAC surgery and received SS-31 (2 mg/d, ip) for 60 d. The right ventricular systolic blood pressure (RVSBP) was measured on d 60 prior to sacrificing the mice; then their right heart and lung tissues were collected for histological and biochemical examinations. Lung injury scores were defined by the increased crowded area and decreased number of alveolar sacs. Results: TAC mice showed significantly higher RVSBP compared with sham-operated mice, the elevation was substantially suppressed in TAC+SS-31 mice. The same pattern of changes was found in pulmonary levels of oxidative stress proteins (NOX-1/NOX-2/oxidized proteins), cytosolic cytochrome c, biomarkers related to inflammation (MMP-9/TNF-α/iNOS), calcium overload index (TRPC1, 2, 4, 6), apoptosis (mitochondrial BAX, cleaved caspase 3/PARP), fibrosis (Smad3/TGF-β), hypoxic (HIF-1α), DNA damage (γ-H2AX) and endothelial function (eNOS/ET-1R), as well as in lung injury score, number of muscularized vessels in lungs, number of TRPC1 + and HIF-1α + cells in pulmonary artery, and number of γ-H2AX + and Ki-67 + cells in lung parenchyma. An opposite pattern of changes was observed in pulmonary anti-fibrotic markers (Smad1/5, BMP-2), number of small vessels, and number of alveolar sacs. In contrast, the levels of antioxidant proteins (HO-1/NQO-1/GR/GPx) in lung parenchyma were progressively and significantly increased from shamoperated mice, TAC mice to TAC+SS-31 mice. Conclusion: Antioxidant peptide SS-31 administration effectively attenuates TAC-induced PAH in mice.

show abstract

Economic Evaluation of Manitoba Health Lines in the Management of Congestive Heart Failure

Cited by 15 publications

References 88 publications

Economic evaluations of eHealth technologies: A systematic review

Economic evaluations of eHealth technologies: A systematic review

Physical activity trails in an urban setting and cardiovascular disease morbidity and mortality in Winnipeg, Manitoba, Canada: a study protocol for a natural experiment

Administration of antioxidant peptide SS-31 attenuates transverse aortic constriction-induced pulmonary arterial hypertension in mice

Contact Info

Product

Resources

About